- In December 2023, QuidelOrtho Corporation received FDA clearance for its VITROS® Anti-SARS-CoV-2 IgG Quantitative Test. This test measures the amount of IgG antibodies to the SARS-CoV-2 virus, providing valuable information for assessing the immune response to infection or vaccination. This clearance enhances QuidelOrtho's portfolio of diagnostic solutions for COVID-19 and highlights the ongoing development of advanced EIA-based tests to address the pandemic.
- In November 2023, DiaSorin launched the LIAISON® XL Anti-SARS-CoV-2 TrimericS IgG assay. This assay is designed to detect IgG antibodies against the trimeric spike protein of SARS-CoV-2, which may offer improved sensitivity and specificity compared to assays targeting other viral antigens. The development of this assay demonstrates DiaSorin's commitment to providing innovative serological tools for COVID-19 research and clinical management.
- In October 2023, Siemens Healthineers introduced the Atellica IM Analyzer, a high-throughput immunoassay system designed to meet the growing demands of clinical laboratories. This analyzer offers a wide range of immunoassay tests, including those based on EIA principles, with enhanced automation and efficiency. The launch of the Atellica® IM Analyzer reflects the industry trend towards increased automation and digitalization in EIA testing.
- In September 2023, Thermo Fisher Scientific expanded its portfolio of Thermo Scientific ELISA kits with the addition of several new assays for detecting biomarkers in various disease areas, including autoimmune disorders, cancer, and infectious diseases. These new ELISA kits are designed to provide researchers with reliable and easy-to-use tools for their studies. This expansion highlights the continued importance of ELISA assays in research and development.
- In August 2023, Bio-Rad Laboratories received CE-IVD mark for its Platelia™ SARS-CoV-2 Total Ab assay. This assay detects total antibodies (IgG, IgM, and IgA) to SARS-CoV-2 and can be used to assess past or present infection. The CE-IVD mark allows for the use of this assay in European markets and further expands Bio-Rad's offerings for COVID-19 diagnostics
